Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Glial fibrillary acidic protein (GFAP) is an established indicator of astrogliosis. Therefore, variable cerebrospinal fluid (CSF) concentrations of this protein might reflect disease-specific pathologic profiles. In patients with narcolepsy, a loss of hypocretin-1 (hcrt-1) neurons in the brain and low concentrations of hcrt-1 in CSF have been reported. We performed a commercially available enzyme-linked immunosorbent assay to investigate if GFAP also is altered in the CSF of these patients. Here we detected significantly higher CSF levels of GFAP in patients with low hcrt-1 levels, of which the majority had a diagnosis of narcolepsy and cataplexy (NC); however, this finding was not observed in patients with hcrt-1 levels that were within reference range. In conclusion, GFAP may be useful as an additional disease biomarker in patients with narcolepsy, and this hypothesis should be investigated in larger studies.

Original publication

DOI

10.1016/j.sleep.2013.04.013

Type

Journal

Sleep Med

Publication Date

07/2013

Volume

14

Pages

692 - 694

Keywords

Astrogliosis, Cataplexy, Cerebrospinal fluid, GFAP, Glial fibrillary acidic protein, Hypocretin-1, Narcolepsy, Adult, Biomarkers, Cataplexy, Enzyme-Linked Immunosorbent Assay, Female, Glial Fibrillary Acidic Protein, Gliosis, Humans, Intracellular Signaling Peptides and Proteins, Male, Middle Aged, Narcolepsy, Neurons, Neuropeptides, Orexins, Young Adult